Citigroup has downgraded Cooper Companies Inc (COO) to Neutral from Buy. The action, taken on August 27, 2025, comes as the company's stock trades at $74.30.
This downgrade underscores growing caution regarding Cooper Companies' outlook. Analysts may be reacting to competitive pressures, market conditions, or execution risks that could affect performance.
Cooper Companies operates as a medical device company, focusing on two segments: CooperVision, which specializes in contact lenses, and CooperSurgical, which provides products and services in fertility and women's health care. The company has a market capitalization of $14.2 billion and a P/E ratio of 34.78, with an EPS of 2.03 and a dividend yield of 1.8%.
Upcoming earnings reports are also on the horizon, with estimates of $1.06 EPS and $1.1 billion in revenue expected on May 27, 2026.
Analyst consensus remains a mix of perspectives, with 5 Strong Buy, 10 Buy, 9 Hold, 1 Sell, and no Strong Sell ratings noted as of November 1, 2025. Recent actions from other firms, such as Wells Fargo and Baird, have maintained their ratings, indicating a varied outlook among analysts.